Charles Moore, MD
Family Medicine · Florence, ALNPI 1629038609
Payments from drug & device makers
Across 97 payments — averaging $30.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Lilly USA, LLC$306
- AbbVie$259
- GSK$204
- Amgen$203
- Johnson & Johnson$146
- plus $652 from 18 others
What the payments were for
- Food & beverage$2,93199%
- Education$351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $1,197 |
| Lilly USA, LLC | 12 | $306 |
| AbbVie | 14 | $259 |
| GSK | 3 | $204 |
| Amgen | 15 | $203 |
| Johnson & Johnson(2 entities) | 3 | $146 |
| Dexcom, Inc. | 1 | $125 |
| Kowa Pharmaceuticals America, Inc. | 1 | $114 |
| Novo Nordisk | 5 | $98 |
| Pfizer | 2 | $34 |
| Bausch Health US, LLC | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| AMAG Pharmaceuticals, Inc. | 2 | $29 |
| Exeltis, USA Inc. | 2 | $27 |
| Astellas Pharma US Inc | 1 | $24 |
| Antares Pharma, Inc. | 1 | $20 |
| Roche Diagnostics Corporation | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Vifor Pharma, Inc. | 1 | $15 |
| Abbott | 1 | $12 |
| Merck | 1 | $12 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$513
- DEXCOM G7 GSS (161)$125
- DEXCOM STELO GLUCOSE BIOSENSOR$125
- ZORYVE$114
How this compares
$2,966 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $80,724 |
| JanuviaSitagliptin Phosphate | 51 | $53,568 |
| TrulicityDulaglutide | 22 | $30,143 |
| MounjaroTirzepatide | 29 | $28,837 |
| XareltoRivaroxaban | 22 | $25,395 |
| OzempicSemaglutide | 23 | $21,682 |
| FarxigaDapagliflozin Propanediol | 19 | $20,057 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $16,647 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $7,322 |
| Atorvastatin Calcium | 290 | $4,487 |
| Omeprazole | 299 | $4,184 |
| Lisinopril | 359 | $3,250 |
| Pravastatin Sodium | 97 | $3,089 |
| Losartan Potassium | 259 | $2,877 |
| Tamsulosin Hcl | 149 | $2,834 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $34 | $80,72487 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $306 | $58,98051 claims |
| MerckJanuvia | $12 | $53,56851 claims |
| Johnson & JohnsonXarelto | $146 | $25,39522 claims |
| Novo NordiskOzempic | $98 | $21,68223 claims |
| AstraZenecaFarxiga | $1,197 | $20,05719 claims |
| GSKTrelegy Ellipta | $204 | $16,64721 claims |
| AbbVieSynthroid | $259 | $2,14121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Florence
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.